Get the Stockscreener App
7.815
18.75%
1.255
Bioventus Inc stock is traded at $7.815, with a volume of 793.06K.
It is up +18.75% in the last 24 hours and up +10.97% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$6.56
Open:
$7.12
24h Volume:
793.06K
Relative Volume:
2.22
Market Cap:
$521.76M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-13.03
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
+12.25%
1M Performance:
+10.97%
6M Performance:
+6.13%
1Y Performance:
-43.18%
1-Day Range:
$7.12
$8.26
1-Week Range:
$6.50
$8.26
52-Week Range:
$5.81
$12.61
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
7.80 | 438.81M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
125.47 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.59 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
360.57 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.02 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
84.37 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Bioventus Outpaces Q3 Expectations And Reaffirms Full-Year Goals - Finimize
Bioventus Q3 2025 slides: 8% organic growth with margins expanding despite flat revenue - Investing.com
Bioventus : Q3'25 Earnings Call Slides - MarketScreener
Bioventus Inc. (BVS) Q3 FY2025 earnings call transcript - Yahoo Finance
Bioventus: Q3 Earnings Snapshot - News-Times
Bioventus Inc Q3 2025 Earnings: EPS of $0.05 Beats Estimate, Rev - GuruFocus
Bioventus tops Q3 expectations as organic revenue grows 8% By Investing.com - Investing.com UK
Bioventus Q3 revenue beats expectations, EPS up 200% - MarketScreener
Bioventus Reports Third Quarter Financial Results - The Manila Times
Bioventus tops Q3 expectations as organic revenue grows 8% - Investing.com
Bioventus Inc. SEC 10-Q Report - TradingView
Bioventus Inc. stock prediction for this weekEarnings Beat & Weekly Watchlist of Top Performers - newser.com
Is Bioventus Inc. stock attractive for income investors2025 Support & Resistance & Momentum Based Trading Signals - newser.com
What the charts say about Bioventus Inc. today2025 Trading Recap & Free Daily Entry Point Trade Alerts - newser.com
Can Bioventus Inc. rally from current levels2025 EndofYear Setup & Safe Capital Investment Plans - newser.com
How strong is Bioventus Inc. stock revenue growthJuly 2025 Technicals & Technical Pattern Alert System - newser.com
Will Bioventus Inc. stock maintain momentum in 2025Market Risk Analysis & Reliable Price Action Trade Plans - newser.com
What To Expect From Bioventus Inc (BVS) Q3 2025 Earnings - Yahoo Finance
Will Bioventus Inc. stock deliver long term returns2025 Volatility Report & Technical Entry and Exit Tips - newser.com
Developing predictive dashboards with Bioventus Inc. dataPortfolio Value Report & Accurate Buy Signal Notifications - newser.com
Bioventus Inc. stock chart pattern explained2025 Earnings Impact & Real-Time Volume Surge Alerts - newser.com
Should you wait for a breakout in Bioventus Inc.Earnings Risk Report & Step-by-Step Trade Execution Guides - newser.com
Can Bioventus Inc. stock sustain free cash flow growth2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
Short interest data insights for Bioventus Inc.July 2025 PostEarnings & Weekly Top Gainers Trade List - newser.com
Why Bioventus Inc. stock is trending among retail tradersBond Market & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Bioventus Inc. with AIInflation Watch & Technical Pattern Alert System - newser.com
Backtesting results for Bioventus Inc. trading strategiesEarnings Recap Summary & Safe Investment Capital Preservation Plans - newser.com
Is Bioventus Inc. stock recession proofQuarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):